Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$114M |
| 2 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$31.3M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$26.4M |
| 4 |
Tyler Technologies
TYL
|
+$25M |
| 5 |
Brown & Brown
BRO
|
+$18.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$249M |
| 2 |
CELG
Celgene Corp
CELG
|
+$231M |
| 3 |
Microsoft
MSFT
|
+$171M |
| 4 |
Alibaba
BABA
|
+$140M |
| 5 |
Amazon
AMZN
|
+$99.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Healthcare | 14.66% |
| 3 | Consumer Discretionary | 11.66% |
| 4 | Communication Services | 10.19% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Natera
NTRA
$45.5B
| $3.16M | ﹤0.01% |
93,900
+2,200
| +2% | +$81.1K |
|
|
LADR
1452
Ladder Capital
LADR
$1.25B
| $3.16M | ﹤0.01% |
175,107
+5,000
| +3% | +$86.3K |
|
1453
Renasant Corp
RNST
$4B
| $3.16M | ﹤0.01% |
89,200
+1,000
| +1% | +$35.3K |
|
1454
Constellium
CSTM
$3.95B
| $3.16M | ﹤0.01% |
235,600
+6,200
| +3% | +$85.6K |
|
1455
Cheesecake Factory
CAKE
$5.84B
| $3.15M | ﹤0.01% |
81,200
+600
| +0.7% | +$24.7K |
|
1456
PRA Group
PRAA
$762M
| $3.15M | ﹤0.01% |
86,900
+1,700
| +2% | +$60.2K |
|
|
ERF
1457
DELISTED
Enerplus Corporation
ERF
| $3.15M | ﹤0.01% |
442,855
-4,500
| -1% | -$29.4K |
|
|
ENLC
1458
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $3.15M | ﹤0.01% |
513,023
+10,000
| +2% | +$60.7K |
|
|
HTLF
1459
DELISTED
Heartland Financial USA, Inc.
HTLF
| $3.14M | ﹤0.01% |
63,200
+1,300
| +2% | +$61.1K |
|
1460
Kite Realty
KRG
$5.27B
| $3.14M | ﹤0.01% |
160,800
+3,300
| +2% | +$59.5K |
|
|
PDCE
1461
DELISTED
PDC Energy, Inc.
PDCE
| $3.14M | ﹤0.01% |
119,966
-4,700
| -4% | -$113K |
|
1462
Werner Enterprises
WERN
$2.31B
| $3.13M | ﹤0.01% |
86,100
+900
| +1% | +$32.9K |
|
|
MDRX
1463
DELISTED
Veradigm Inc. Common Stock
MDRX
| $3.13M | ﹤0.01% |
319,000
+6,700
| +2% | +$70.6K |
|
1464
Pricesmart
PSMT
$5.49B
| $3.12M | ﹤0.01% |
43,900
+1,000
| +2% | +$71.9K |
|
1465
Kratos Defense & Security Solutions
KTOS
$11.8B
| $3.11M | ﹤0.01% |
172,600
+3,600
| +2% | +$66.8K |
|
1466
Gibraltar Industries
ROCK
$1.46B
| $3.11M | ﹤0.01% |
61,600
+1,200
| +2% | +$60.3K |
|
1467
AppFolio
APPF
$6.97B
| $3.1M | ﹤0.01% |
28,200
+1,200
| +4% | +$122K |
|
1468
United Parks & Resorts
PRKS
$2.01B
| $3.1M | ﹤0.01% |
97,800
-5,000
| -5% | -$144K |
|
1469
Champion Homes
SKY
$5.1B
| $3.1M | ﹤0.01% |
97,700
+2,000
| +2% | +$62.3K |
|
1470
Cactus
WHD
$5.78B
| $3.09M | ﹤0.01% |
90,100
+2,200
| +3% | +$66.8K |
|
|
ADAM
1471
Adamas Trust
ADAM
$913M
| $3.09M | ﹤0.01% |
123,880
+15,400
| +14% | +$382K |
|
1472
Aurinia Pharmaceuticals
AUPH
$2.06B
| $3.08M | ﹤0.01% |
152,500
+30,500
| +25% | +$281K |
|
1473
HUTCHMED
HCM
$2.13B
| $3.08M | ﹤0.01% |
122,787
-48,800
| -28% | -$1.07M |
|
|
ITCI
1474
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.08M | ﹤0.01% |
89,700
+2,800
| +3% | +$33.6K |
|
|
AVNS
1475
DELISTED
Avanos Medical
AVNS
| $3.08M | ﹤0.01% |
91,300
+2,100
| +2% | +$76K |
|
Similar funds
Swiss National Bank's Q4 2019 Portfolio in Review
As of Q4 2019, Swiss National Bank held 2,602 positions worth $97.5B, up 3.6% from $94.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Swiss National Bank withdrew a net $3.98B in Q4 2019, closing 96 positions and reducing 725 holdings. Its most notable exit was Celgene Corp, an estimated $231M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in Match Group worth $14.7M.
- Swiss National Bank's largest Q4 2019 buy was Match Group: 179,200 shares worth $14.7M.
- Swiss National Bank added most to Bristol-Myers Squibb in Q4 2019, an estimated $114M increase.
- Swiss National Bank's biggest Q4 2019 reduction was Apple, cutting an estimated $249M.
- Swiss National Bank fully exited Celgene Corp in Q4 2019, selling an estimated $231M.
- Swiss National Bank's ten largest holdings make up 19% of its $97.5B portfolio in Q4 2019.
- Swiss National Bank opened 82 new positions and closed 96 in Q4 2019.
- Swiss National Bank's portfolio value rose 3.6% quarter-over-quarter to $97.5B.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.